# US 2013/0252918 A1 · Phosphoramidite derivatives of gemcitabine for use in the treatment cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252918 A1
- Document ID: US20130252918A1
- Status: Published application
- Kind: A1
- Application number: 13/877,673
- Filed: 2011-10-05
- Published: 2013-09-26
- Earliest claimed: 2010-10-06
- Assignees: NuCana BioMed Limited
- Inventors: Christopher McGuigan
- Web page: https://patentgrep.com/patent/US20130252918A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61P 35/00: Antineoplastic agents
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR′R″ where R′ is H and R″ is CR5R6CO2R7, where R6 is H, R5 is the side chain, including H and C1, of a naturally occurring alpha amino acid, and R7 is branched or unbranched, substituted or unsubstituted, acyclic or cyclic alkyl, including t-butyl-CH2-, benzyl and C3 to C6 cycloalkyl. Formula (I).

## Claims

### Claim 1

A chemical compound having formula I:
wherein:
R2 is selected from CR5R6CO2R7 and C1-C6 alkyl and R1 is selected from H and C1-C6 alkyl,
or R1 and R2 together with the N atom to which they are attached form a ring moiety comprising 5 to 8 ring atoms;
R4 is selected from CR5R6CO2R7 and C1-C6 alkyl and R3 is selected from H and C1-C6 alkyl,
or R3 and R4 together with the N atom to which they are attached form a ring moiety comprising 5 to 8 ring atoms;
where, independently for each of R2 and R4:
R5 and R6 are selected, independently, from the side chains of naturally occurring alpha amino acids, and
R7 is selected from C1-C18 alkyl;
Y is selected from H and C(O)R, where R is C1-C18 alkyl;
Z is selected from H and C(O)R, where R is C1-C18 alkyl,
or a pharmaceutically acceptable derivative thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 where R2 and R4 are the same.

### Claim 3 (depends on 1)

A compound according to claim 1 where R2 and R4 are each CR5R6CO2R7.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein R7 is selected from the group comprising branched and unbranched C1-C18 acyclic alkyl and C3-C8 cyclic alkyl, any of which acyclic alkyl and cyclic alkyl moieties may be substituted and/or unsaturated.

### Claim 5 (depends on 4)

A compound according to claim 4 wherein R7 is selected from methyl, ethyl, i-propyl, t-butyl-CH2—, benzyl and C3-C6 cycloalkyl.

### Claim 6 (depends on 5)

A compound according to claim 5 where R7 is t-butyl-CH2—.

### Claim 7 (depends on 1)

A compound according to claim 1 wherein R6 is H and R5 is selected from the side chains of naturally occurring alpha amino acids.

### Claim 8 (depends on 7)

A compound according to claim 7 wherein R6 is H and R5 is selected from H, methyl, i-propyl, —CH2Ph, —CH2CH(CH3)2 and —CH(CH3)(C2H5).

### Claim 9 (depends on 8)

A compound according to claim 8 wherein R6 is H and R5 is methyl.

### Claim 10 (depends on 9)

A compound according to claim 9 wherein R7 is selected from methyl, ethyl, i-propyl, t-butyl-CH2—, benzyl and C3-C6 cycloalkyl.

### Claim 11 (depends on 10)

A compound according to claim 10 wherein R7 is t-butyl-CH2—.

### Claim 12 (depends on 1)

A compound according to claim 1 where the compound has natural L stereochemistry at *CR5R6.

### Claim 13 (depends on 1)

A compound according to claim 1 wherein the compound has D stereochemistry at *CR5R6.

### Claim 14 (depends on 1)

A compound according to claim 1 wherein each of R5 and R6 is methyl.

### Claim 15 (depends on 1)

A compound according to claim 1 wherein each of R1 and R3 is the same.

### Claim 16 (depends on 15)

A compound according to claim 15 wherein each of R1 and R3 is H.

### Claim 17 (depends on 16)

A compound according to claim 16 wherein each of R1 and R3 is H and each of R2 and R4 is CR5R6CO2R7.

### Claim 18 (depends on 17)

A compound according to claim 17 wherein each of R1 and R3 is H and each of R2 and R4 is CR5R6CO2R7 wherein R6 is H and R5 is selected from the side chains of naturally occurring alpha amino acids.

### Claim 19 (depends on 18)

A compound according to claim 18 wherein R5 is selected from H, methyl, i-propyl, CH2Ph, —CH2CH(CH3)2 and —CH(CH3)(C2H5).

### Claim 20 (depends on 19)

A compound according to claim 19 wherein R7 is selected from the group comprising methyl, ethyl, i-propyl, t-butyl-CH2—, benzyl and C3-C6 cycloalkyl.

### Claim 21 (depends on 1)

A compound according to claim 1 wherein R1 and R2 together with the N atom to which they are attached form a ring moiety comprising 5 to 8 ring atoms and R3 and R4 together with the N atom to which they are attached form a ring moiety comprising 5 to 8 ring atoms.

### Claim 22 (depends on 1)

A compound according to claim 1 wherein each of Y and Z is H.

### Claim 23

A compound selected from the group consisting of:
2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-bis(ethoxy-L-alaniny1)-phosphate;
2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-bis(benzoxy-L-alaniny1)-phosphate;
2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-bis(cyclohexoxy-L-alaniny1)-phosphate;
2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-bis(2,2-dimethylpropoxy-L-alaniny1)-phosphate; and
2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-bis(iso-propoxy-L-alaninyl)-phosphate.

### Claim at position 24

-25. (canceled)

### Claim 26 (depends on 1)

A method of prophylaxis or treatment of cancer comprising administering to a patient in need of such prophylaxis or treatment an effective dose of a compound according to claim 1.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 28 (depends on 1)

A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 1 with a pharmaceutically acceptable excipient, carrier or diluent.

### Claim 29 (depends on 1)

A process for preparing a compound of formula I according to claim 1, the process comprising reacting with phosphoryl chloride (POCl3) a compound of formula (II):
followed by reaction with R1R2NH and R3R4NH
wherein
R1, R2, R3, R4, R5, R6, R7, R, Y and Z have the meanings described in claim 1.
